Abemaciclib plus fulvestrant in East Asian women with HR+, HER2− advanced breast cancer: Overall survival from MONARCH 2

MONARCH 2 is a global, randomized, double‐blind, phase 3 study of abemaciclib/placebo + fulvestrant in patients with hormone receptor positive, human epidermal growth factor receptor 2‐negative advanced breast cancer. The East Asian population comprised 212 (31.7%) of the 669 intent‐to‐treat populat...

Descripción completa

Detalles Bibliográficos
Autores principales: Toi, Masakazu, Huang, Chiun‐Sheng, Im, Young‐Hyuck, Sohn, Joohyuk, Zhang, Wei, Sakaguchi, Sachi, Haddad, Nadine, van Hal, Gertjan, Sledge, George W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807498/
https://www.ncbi.nlm.nih.gov/pubmed/36168844
http://dx.doi.org/10.1111/cas.15600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807498/
https://www.ncbi.nlm.nih.gov/pubmed/36168844
http://dx.doi.org/10.1111/cas.15600

Ejemplares similares